Procleix assays expand blood screening with a comprehensive NAT assay portfolio. The NAT solutions portfolio provides screening of: HIV-1, HIV-2, HCV, HBV, WNV, Parvovirus B19, HAV, HEV, Dengue Virus, Zika Virus, SARS-CoV-2, and Babesia.
Release Products Faster Than With Batched Systems
In a screening world where pathogens require screening before the release of blood products, the portfolio of Procleix systems allow for back-to-back assay testing within the same worklist to ensure faster time to a full set of results.
Back-to-back results from the same sample when multiple assay results are needed
Process up to four assays from the same sample, at the same time, on the same system
Allow for more efficient management of the daily workload
The costs for recruiting donors and waste disposal are often overlooked. The Procleix assay portfolio helps blood banks reduce the cost of NAT screening.
Low input sample volume (0.5 mL needed per test) reduces the need to draw more sample from the blood bag
Single-tube processing means less solid waste to dispose of, fewer moving parts, and less maintenance
Isothermal TMA technology – better reproducibility
Reduce hazardous liquid disposal costs – liquid waste can be poured down the drain
Up to 24 months* shelf life means less lot release validation and easier inventory management
*with the exception of the Procleix UltrioPlex E assay.